Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.73 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | PGR | P06401 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | SHBG | P04278 | 3/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.60 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8712243 | 1.00 | HIF1A (0.73) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 | |
| SCHEMBL27991637 | 1.00 | HIF1A (0.73) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 | |
| SCHEMBL141635 | 1.00 | HIF1A (0.73) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 | |
| SCHEMBL147438 | 0.91 | HIF1A (0.72) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 | |
| SCHEMBL10597610 | 0.91 | HIF1A (0.72) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 | |
| SCHEMBL10062395 | 0.91 | HIF1A (0.72) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 | |
| SCHEMBL11641738 | 0.91 | HIF1A (0.64) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 | |
| SCHEMBL10597597 | 0.91 | HIF1A (0.72) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 | |
| SCHEMBL11641729 | 0.91 | HIF1A (0.64) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 | |
| SCHEMBL3649005 | 0.91 | HIF1A (0.72) | HIF1ANR3C2SERPINA6NR3C1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| US-11576907-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220151955-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | THE KETAMINE RESEARCH FOUNDATION | 2022-05-19 | — | — | US | disclosed |
| EP-3851107-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210169872-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210113493-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | WOLFSON PHILIP E (US) | 2021-04-22 | — | — | US | disclosed |
| US-10456392-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-9956216-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170273972-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | COMBINATORX, INCORPORATED | 2005-08-25 | — | — | US | disclosed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| US-4181669-A | A CARBODIIMIDE WITH ACID CATALYSTS AS A CONDENSATION AGENT | AKTIEBOLAGET LEO (SE) | 1980-01-01 | — | — | US | disclosed |
| US-4180504-A | Method for the preparation of esters | AKTIEBOLAGET LEO (SE) | 1979-12-25 | — | — | US | disclosed |
| US-3984544-A | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor | SCHERING CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
| US-3971772-A | ANTINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-07-27 | — | — | US | disclosed |
| US-3971773-A | Steroidal 9,11-dihalo-[16α,17-b]1,4-dioxanes | E. R. SQUIBB & SONS, INC. (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169872-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | HIF1A 4646/4885NR3C2 2/4885SERPINA6 84/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | HIF1A 1602/4885NR3C2 796/4885SERPINA6 12/4885 |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | IL5, TNF, LTC4S | HIF1A 2333/4885NR3C2 59/4885SERPINA6 5/4885 |
| US-20170273972-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | HIF1A 4646/4885NR3C2 2/4885SERPINA6 84/4885 |
| US-11576907-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, NR3C2, NR5A1 | HIF1A 4646/4885NR3C2 2/4885SERPINA6 84/4885 |
| US-20220151955-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | OXTR, PNISR, KCNQ5 | HIF1A 1138/4885NR3C2 648/4885SERPINA6 2228/4885 |
| US-10456392-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, NR3C2, NR5A1 | HIF1A 4646/4885NR3C2 2/4885SERPINA6 84/4885 |
| US-20210113493-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | KCNK5, KCNQ5, KCND2 | HIF1A 563/4885NR3C2 1213/4885SERPINA6 1674/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | HIF1A 1602/4885NR3C2 796/4885SERPINA6 12/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | HIF1A 1602/4885NR3C2 796/4885SERPINA6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.